


CLAIMS

1. Use of a therapeutically effective amount of a compound of Formula (I) in the manufacture of a medicament for treating a disease or a condition in a patient in need thereof, wherein the disease or condition is selected from atopic dermatitis, bladder dysfunction associated with multiple sclerosis, cardiovascular disease, contact dermatitis, cystic fibrosis, dermatomyositis, eczema, endometriosis, enteritis, fibromyalgia, Tourette syndrome, inflammatory bowel disease, interstitial cystitis, irritable bowel syndrome, ischemia, labor, abdominal pain, abdominal pain associated with irritable bowel syndrome, acute pain, back pain, cancer pain, chest pain, functional chest pain, joint pain, menstrual pain, metabolic disorders, musculoskeletal diseases, neuropathy, osteoarthritis, pancreatitis, pharyngitis, post mastectomy pain syndrome, post trigeminal neuralgia, post operative pain, renal ischemia, rheumatoid arthritis, skeletal muscle contusion, skin diseases, sunburn, systemic lupus erythematosus, toothache, vasoocclusive painful crises in sickle cell disease, and visceral pain, wherein the compound of Formula (I) comprises the structure:




Formula (I);

wherein:

R¹ is -C(O)OR¹⁵ or -C(O)NR¹⁰R¹¹;

R² is H, halogen, C₁₋₆alkyl, or C₁₋₆haloalkyl;



A is N or C(H);

X is -O-, -N(R¹⁶)-, or -CH₂N(R¹⁶)CH₂-;

Y is -CH₂- or -C(O)-;

Z is -S-, -O-, or -N(R¹⁸)-;

R⁴ is H, halogen, -OR⁷, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, -C(O)NR⁸R⁹, C₃₋₈cycloalkyl, C₂₋₉heterocycloalkyl, -C₁₋₆alkyl-C₂₋₉heterocycloalkyl, C₆₋₁₀aryl, or C₁₋₉heteroaryl, wherein C₃₋₈cycloalkyl, C₂₋₉heterocycloalkyl, -C₁₋₆alkyl-C₂₋₉heterocycloalkyl, C₆₋₁₀aryl, or C₁₋₉heteroaryl are optionally substituted with 1 or 2 R¹⁴;

R⁵ is H, halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, C₁₋₆haloalkoxy, or phenyl;

R⁶ is H, halogen or C₁₋₆alkyl;

R⁷ is H, C₁₋₆alkyl, C₁₋₆haloalkyl, -C₁₋₆alkyl-OH, C₂₋₉heterocycloalkyl, C₆₋₁₀aryl, or C₁₋₉heteroaryl, wherein C₂₋₉heterocycloalkyl, C₆₋₁₀aryl, or C₁₋₉heteroaryl are optionally substituted with 1 or 2 R¹⁴;

each R⁸ and each R⁹ are independently selected from H and C₁₋₆alkyl; or R⁸ and R⁹ together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;

R¹⁰ and R¹¹ are each independently H or C₁₋₆alkyl;

R¹² is H, halogen, or C₁₋₆alkyl;

R¹³ is H or C₁₋₆alkyl;

each R¹⁴ is independently selected from halogen, -OH, C₁₋₆alkyl, C₁₋₆haloalkyl, C₁₋₆alkoxy, -C₁₋₆alkyl-OH, C₃₋₈cycloalkyl, -C(O)OH, -C(O)NR⁸R⁹, -SO₂-C₁₋₆alkyl, and -N(R¹⁷)C(O)-C₁₋₆alkyl;

R¹⁵ is H or C₁₋₆alkyl;

R¹⁶ is H, C₁₋₆alkyl, -C(O)-C₁₋₆alkyl, -C₁₋₆alkyl-OH, or -CH₂CO₂H;

R¹⁷ is H or C₁₋₆alkyl;

R¹⁸ is H or C₁₋₆alkyl;

v is 0 or 1;

n is 0 or 1;


m is 0 or 1;

p is 0, 1, or 2; and

q is 0, 1 or 2;


or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

2. The use of claim 1, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically




acceptable salt thereof, wherein R^3 is

3. The use of claim 1 or 2, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein m is 1, n is 1, q is 0, and p is 2.
4. The use of any one of claims 1-3, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein Y is $-\text{CH}_2-$ and A is $\text{C}(\text{H})$.
5. The use of any one of claims 1-4, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^{12} is H and R^{13} is H .
6. The use of any one of claims 1-5, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^4 is halogen, $-\text{OR}^7$, C_{1-6} haloalkyl, C_{2-9} heterocycloalkyl, C_{6-10} aryl, or C_{1-9} heteroaryl, wherein C_{2-9} heterocycloalkyl, C_{6-10} aryl, or C_{1-9} heteroaryl are optionally substituted with 1 or 2 R^{14} .
7. The use of any one of claims 1-6, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^4 is halogen or R^4 is C_{2-9} heterocycloalkyl optionally substituted with 1 or 2 R^{14} .
8. The use of any one of claims 1-7, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^2 is H , R^6 is H , and R^5 is H , halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, or C_{1-6} haloalkoxy.
9. The use of any one of claims 1-8, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^1 is $-\text{C}(\text{O})\text{OR}^{15}$ and R^{15} is H .
10. The use of claim 1, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically




acceptable salt thereof, wherein the compound is ; or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

11. The use of claim 1, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically




acceptable salt thereof, wherein the compound is ; or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

12. The use of claim 1, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically




acceptable salt thereof, wherein the compound is
tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

13. The use of claim 1, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically




acceptable salt thereof, wherein the compound is
tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.


14. The use of claim 1, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically




acceptable salt thereof, wherein the compound is
tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.


15. The use of claim 1, wherein the compound is selected from:










































or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.